Search

Your search keyword '"Neuzil, Kathleen"' showing total 1,252 results

Search Constraints

Start Over You searched for: Author "Neuzil, Kathleen" Remove constraint Author: "Neuzil, Kathleen"
1,252 results on '"Neuzil, Kathleen"'

Search Results

1. Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.

2. Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

3. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial

4. Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

5. Risk of COVID-19 after natural infection or vaccination

6. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.

7. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.

8. Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens

9. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

10. Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial

11. Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum

12. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.

13. Using time‐weighted average change from baseline of SARS‐CoV‐2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID‐19

14. Self-Assessed Severity as a Determinant of Coronavirus Disease 2019 Symptom Specificity: A Longitudinal Cohort Study

15. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

16. Safety and immunogenicity of a single dose of Tdap compared to Td in pregnant women in Mali and 3 its effect on infant immune responses: a single-centre, randomised, double-blind, active-controlled phase 2 study

17. Using social contact data to improve the overall effect estimate of a cluster-randomized influenza vaccination program in Senegal

18. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

19. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

20. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children

21. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection

22. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

23. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

24. Risk of COVID-19 after natural infection or vaccination

25. Typhoid fever

26. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

27. Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

28. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

30. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

33. Contributors

35. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial

40. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial

41. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial

42. Safety and immunogenicity of co-administration of meningococcal type A and measles–rubella vaccines with typhoid conjugate vaccine in children aged 15–23 months in Burkina Faso

43. Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9–12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial

44. Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials

46. Quantitative analysis of pertussis, tetanus, and diphtheria antibodies in sera and breast milk from Tdap vaccinated women using a qualified multiplex assay

47. COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials

48. Reply to Skowronski and De Serres

Catalog

Books, media, physical & digital resources